The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation

This publication has 25 references indexed in Scilit:

• Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2
  Transplantation, 2003
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
  Clinical Pharmacology & Therapeutics, 2003
• The Pharmacogenetics of Immunosuppression for Organ Transplantation
  American Journal of PharmacoGenomics, 2003
• Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement
  Transplantation, 2002
• Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation
  Nephrology Dialysis Transplantation, 2001
• ABSORPTION PROFILING OF CYCLOSPORINE MICROEMULSION (NEORAL) DURING THE FIRST 2 WEEKS AFTER RENAL TRANSPLANTATION1
  Transplantation, 2001
• Tacrolimus whole blood concentrations correlate closely to side‐effects in renal transplant recipients
  British Journal of Clinical Pharmacology, 1999
• The Banff 97 working classification of renal allograft pathology
  Kidney International, 1999
• RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1
  Transplantation, 1998
• Racial variation in dosage requirements of tacrolimus
  The Lancet, 1996